

Express Mail Label No.: EV39952522SUS

1 of 2

Date of Deposit: January 7, 2005

/ Please type a plus sign (+) in this box

PTO/SB (12-97)  
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	10/628,965
	Filing Date	07/28/03
	First Named Inventor	Keller
	Group Art Unit	1616
	Examiner Name	Haghighatian
	Attorney Docket Number	28069-606 CON

## U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

## FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
M	B1	EP 0 416 950	Glaxo Group Limited	September 7, 1990	X
I	B2	EP 0 416 951	Glaxo Group Limited	September 7, 1990	X
	B3	WO 93/11773	Aktiebolaget Astra	June 24, 1993	X
M	B4	WO 00/53157	Chiesi Farmaceutici S.P.A.	September 14, 2000	X

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
M	C1	Adjei and Gupta, In <u>Inhalation Delivery of Therapeutic Peptides and Proteins</u> , Adjei and Gupta eds., Marcel Dekker, Inc., New York, 1997, Chapter 22, pages 625-637.
M	C2	Bolhuis and Lerk (1981). <i>J. Pharm. Pharmacol.</i> 33: 790.
M	C3	Braun et al. (1996). <i>Int. J. Pharm.</i> 135: 53-62.
	C4	<del>British Pharmacopoeia, pages 1173-1174.</del> Year?
M	C5	Byron, In <u>Respiratory Drug Delivery</u> , Byron ed., CFC Press, Inc., Boca Raton, 1990, pages 169-170.
	C6	Chowhan and Chi (1986). <i>J. Pharm. Sci.</i> 75: 534-541.
	C7	Ganderton (1969). <i>J. Pharm. Pharmac.</i> 21: 9S-18S.
M	C8	Geuns et al. (1997). <i>European J. Pharm. and Biopharm.</i> 44: 187-194.
	C9	<del>Guideline 3AQ15a, Stability Testing of New Active Substances and Medicinal Products, pages 127-141.</del> Year?
	C10	<del>Guideline 3AQ16a, Stability Testing on Active Substances and Finished Products, pages 143-145-151.</del> Year?
M	C11	Handbook of Pharmaceutical Excipients, 2 <sup>nd</sup> ed., 1994, pages 280-282.
	C12	Hickey et al. (1994). <i>Pharma. Tech.</i> pages 58, 60, 62-64, and 82.
	C13	Mahmoud and El-Shaboury (1985). <i>Acta. Pharm. Fenn.</i> 94: 125-131.
M	C14	<u>Martindale: The Extra Pharmacopoeia</u> , 28 <sup>th</sup> ed., Reynolds ed., The Pharmaceutical Press, London, 1993, Abstract 6022-f.
	C15	<del>Material Safety Data Sheet, Magnesium Stearate, Spectrum.</del> Year?
M	C16	Meakin et al. (1995). <i>Int. J. Pharm.</i> 119: 103-108.
	C17	MIMS (Monthly Index of Medical Specialties), November 1996, pages 244-245.
M	C18	MIMS (Monthly Index of Medical Specialties), October 1998, pages 271-273.

Date of Deposit: January 7, 2005

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
M	C19	Murthy and Samyn (1977). <i>J. Phar. Sci.</i> 66: 1215-1219.
	C20	Note for Guidance on Development Pharmaceuticals, European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, CPMP/QWP/155/96, January 28, 1998.
	C21	Note for Guidance on Dry Powder Inhalers, European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, CPMP/QWP/158/96, June 24, 1998.
	C22	Peart et al. (1997). <i>Pharm. Res.</i> 14: S-142-S-143, Abstract No. 1405.
	C23	<i>Pharmaceutics: The Science of Dosage Form Design</i> , ed. Michael E. Aulton, Churchill Livingstone, Edinburgh, London, Melbourne and New York, 1988, page 56.
	C24	Price et al. (2002). <i>Int. J. Pharm.</i> 246: 47-59.
	C25	Remington's <i>Pharmaceutical Sciences</i> , 18 <sup>th</sup> ed., 1990, Chapter 31, pages 589,593, and 602; Chapter 76, pages 1451-1452; and Chapter 89, pages 1633, 1636, and 1637.
	C26	<i>Respiratory Drug Delivery II</i> , paper presented by John N. Staniforth at a meeting in Keystone, CO, March 26-30, 1990.
	C27	Statutory Declaration from Professor David Ganderton, December 15, 2003, In the Matter of an opposition by Vectura Limited to EP 1 131 059 in the name of Jago Research AG.
	C28	van Kamp et al. (1986). <i>Pharm. Acta. Helv.</i> 61: 22-29.
	C29	Young et al. (2003). <i>J. Pharm. Sci.</i> 92: 815-822.
M	C30	Zeng et al., In <i>Particulate Interactions in Dry Powder Formulations for Inhalation</i> , Taylor and Francis, Inc., New York, 2001, Sections 1.6.7 (pages 23-24) and 5.5.6 (pages 163-165).

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	5/12/05
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.